Day One Biopharmaceuticals, Inc. (DAWN)
Apr 21, 2026 - DAWN was delisted (reason: acquired by Servier)
21.53
+0.04 (0.19%)
Inactive · Last trade price on Apr 22, 2026
DAWN Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 197.08 | 124.97 | 230.78 | 85.26 | 284.31 |
Short-Term Investments | 244.04 | 406.75 | 135.56 | 257.01 | - |
Cash & Short-Term Investments | 441.11 | 531.72 | 366.35 | 342.27 | 284.31 |
Cash Growth | -17.04% | 45.14% | 7.03% | 20.39% | 550.18% |
Receivables | 26.74 | 13.88 | - | - | - |
Inventory | 6.33 | 3.32 | - | - | - |
Prepaid Expenses | 4.46 | 5.2 | 3.27 | 2.6 | 2.96 |
Other Current Assets | 6.46 | 8.22 | 5.66 | 3.01 | 2.1 |
Total Current Assets | 485.1 | 562.33 | 375.27 | 347.87 | 289.37 |
Property, Plant & Equipment | 4.48 | 4.71 | 0.56 | 0.72 | 0.28 |
Other Intangible Assets | 18.02 | 15.63 | - | - | - |
Other Long-Term Assets | 0.23 | 0.12 | 0.21 | 0.47 | 0.17 |
Total Assets | 507.83 | 582.79 | 376.05 | 349.06 | 289.82 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.73 | 3.26 | 2.58 | 0.26 | 1.74 |
Accrued Expenses | 54.62 | 68.63 | 25.48 | 15.77 | 6.61 |
Current Portion of Leases | 0.17 | 0.01 | 0.41 | 0.41 | 0.2 |
Current Unearned Revenue | 2 | 1.55 | - | - | - |
Other Current Liabilities | - | - | 1.04 | 0.18 | 0.1 |
Total Current Liabilities | 60.52 | 73.45 | 29.51 | 16.62 | 8.66 |
Long-Term Leases | 2.62 | 2.59 | - | 0.41 | 0.02 |
Long-Term Unearned Revenue | 3.04 | 3.23 | - | - | - |
Other Long-Term Liabilities | 0.48 | 0.76 | - | - | - |
Total Liabilities | 66.67 | 80.04 | 29.51 | 17.02 | 8.67 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 1,102 | 1,057 | 805.11 | 601.77 | 408.63 |
Retained Earnings | -661.4 | -554.08 | -458.59 | -269.67 | -127.49 |
Comprehensive Income & Other | 0.07 | 0.08 | 0.01 | -0.07 | - |
Total Common Equity | 441.16 | 502.75 | 346.54 | 332.04 | 281.15 |
Shareholders' Equity | 441.16 | 502.75 | 346.54 | 332.04 | 281.15 |
Total Liabilities & Equity | 507.83 | 582.79 | 376.05 | 349.06 | 289.82 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.79 | 2.6 | 0.41 | 0.81 | 0.22 |
Net Cash (Debt) | 438.32 | 529.12 | 365.94 | 341.46 | 284.09 |
Net Cash Growth | -17.16% | 44.59% | 7.17% | 20.19% | 555.70% |
Net Cash Per Share | 4.25 | 5.68 | 4.59 | 5.22 | 7.69 |
Filing Date Shares Outstanding | 103.3 | 101.35 | 87.38 | 73.59 | 61.95 |
Total Common Shares Outstanding | 102.98 | 101.12 | 87.23 | 73.46 | 61.95 |
Working Capital | 424.58 | 488.88 | 345.77 | 331.26 | 280.71 |
Book Value Per Share | 4.28 | 4.97 | 3.97 | 4.52 | 4.54 |
Tangible Book Value | 423.14 | 487.12 | 346.54 | 332.04 | 281.15 |
Tangible Book Value Per Share | 4.11 | 4.82 | 3.97 | 4.52 | 4.54 |
Machinery | - | - | - | - | 0.08 |
Leasehold Improvements | - | - | - | - | 0.02 |